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Peroxisome proliferator-activated receptors (PPARs) belong to a family of nuclear hormone receptors acting as transcriptional
factors, recently involved also in carcinogenesis. Present study was undertaken to evaluate the presence and subcellular localization
of diﬀerent PPAR isoforms (α, β, γ) in healthy endometrial tissue (n = 10) and endometrial carcinoma (FIGO I, endometrioides
type,G1,n = 35).WesoughttoanalyzePPARsmRNAcontentaswellasproteinimmunohistochemicalexpressionthatwasfurther
quantiﬁed by Western Blot technique. For both PPARα and PPARβ, protein expression was signiﬁcantly higher in endometrial
cancers compared to normal endometrial mucosa. In opposite, PPARγ protein expression was lower in endometrial cancer cells.
In each case, immunohistochemical reaction was conﬁned to the perinuclear and/or nuclear region. At the transcriptional level,
the content of mRNA of all PPAR subunits did not follow the protein pattern of changes. These results provide evidence for altered
PPAR’s protein expression and disregulation of posttranslational processes in endometrial cancers.
1.Introduction
Peroxisome proliferator-activated receptors (PPARs) are
ligand-activated transcription factors of the nuclear hor-
mone receptor superfamily [1, 2]. Three distinct PPAR
isoforms termed α, β/δ,a n dγ have been identiﬁed [3–5].
They share several structural common features, but each is
distinctly expressed in diﬀerent tissues. PPARα and γ are
predominantly expressed in heart, muscles, liver, and in
adipocytes [3–5]. PPARβ is more ubiquitously expressed,
but shares certain common downstream eﬀects with PPARα
[4, 5]. For both PPARα and β, it has been shown that their
activation is responsible for the enhancements in energy
substrate utilization [4]. This ability of PPARs to regulate
cellularmetabolism leads to the question, whether the tumor
cellshavealteredPPARexpression.Itistemptingtospeculate
so, since high energy substrate consumption is a well-known
feature of neoplastic cells, especially these with high rates of
cell proliferation. Indeed, a growing number of researches
begin to suggest an important role of PPAR activation in the
biology of the neoplastic process. Furthermore, some studies
oﬀer the prospect of using PPAR as a destination point of
action for both prevention and treatment of cancers [6–9].
Endometrial cancer (EC) is one of the most widespread
gynecologic cancers in Europe, and according to FIGO
classiﬁcation (International Federation of Gynecology and
Obstetrics) as well as Bokhman theory [10]e n d o m e t r i a l
cancer—endometrioid type (FIGO stage I, type I) is the
most frequent. In addition, EC is usually present with well-
diﬀerentiated morphology (G1) along with an endometrioid
features [10]. Based on that we sought to investigate PPARs
expression in this type of cancer. We examined diﬀerent
PPAR (α, β/δ,γ) isoforms expression at the level of transcrip-
tion (mRNA) and proteins (by immunohistochemistry and
Western Blot technique).
2.MaterialandMethods
The present study conforms with the principles outlined
in the Declaration of Helsinki and was approved by the2 PPAR Research
Ethical Committee for Human Studies of the Medical
University of Bialystok. The patients suspected to have
the cancer of corpus uteri were examined in outpatient
clinic, and biopsies were taken for routine histopathological
examination. Standard histopathological parameters were
determined by two independent pathologists. Based on this
evaluation the two groups of women were included for the
analysis: (a) patients with endometrial cancer (n = 35)
and (b) patients with normal endometrial tissues (control
group, n = 10). In the group of diagnosed EC, cases
with type endometrioid, FIGO I, grade 1, were included in
the study. Control endometrial tissue was gathered during
nononcological operations, mostly because of ﬁbroids. In
each case, endometrial cancer risk factors such as age, the
presence of hypertension, obesity, and type 2 diabetes were
evaluated.
2.1. RNA Extraction and cDNA Synthesis. Total RNA was
extracted from frozen endometrial malignant and normal
tissues according to Chomczynski and Sacchi method [11].
RNA integrity was veriﬁed by elecrophoresis in 1.5%
agarose gel and staining with ethidium bromide, and by
ampliﬁcation of housekeeping gene, 18s rRNA, 1μgo f
total RNA was used to prepare cDNA. cDNA synthesis was
performed in 50mM Tris-HCL (pH 8.3), 75mM KCl, 3mM
MgCl2, 10mM DTT 1mM dNTP mix (Promega), 2.5μM
oligo dT15, 20U RNasin Ribonuclease Inhibitor (Promega),
and 100 U MMLV Reverse Transcriptase (Promega) in a
ﬁnal volume of 40μl using MJ Research Thermal Cycler
(Model PTC-200, Watertown, Massachusetts, USA). For
reverse transcription, the mixtures were incubated at 42◦C
for 60min and then heated at 95◦Cf o r5 m i na n dﬁ n a l l y
rapidly cooled at 4◦C. To determine the mRNA level of
PPARs we used Assays-on-Demand Gene Expression Assay
Mix (Applied Biosystems). All real-time PCR reactions were
performedusingABIPrism7000SequenceDetectionSystem
(Perkin-ElmerAppliedBiosystems,USA).ForeachPCRrun,
a master mix was prepared with 10μl 2x Taq Man Universal
PCR Master Mix (Applied Biosystems), 1μl 20x Assays-on-
Demand Gene Expression Assay Mix (Applied Biosystems),
5μl cDNA, and sterile water to ﬁnal volume of 20μl. The
relative quantiﬁcation was given by the ratio between the
mean value of the target gene and the mean value of the
reference gene for each sample. PCR products were obtained
by ampliﬁcation of cDNA from normal endometrial tissue
using speciﬁc primers as follows: sense: 5 -CGA GGC CGG
CGA TCT AG-3 ; antisense: 5 -ACG CGG GGA CTC CGT
AAT G-3  for PPAR-α sense: 5 -CAT GGA GCA GCC ACA
GGA G-3 , antisense: 5 -TGC ATG AAC ACC GTA GTG
GAA G-3  for PPAR-β:s e n s e :5  -CAA GGC TTC ATG ACA
AGG GAG-3 , antisense: 5 -CGT GTT CCG TGA CAA TCT
GTCT-3  forPPAR-γ.PCRwascarriedoutinﬁnalvolumeof
50μl using 25pmol of each of the primers, 40μMo fe a c ho f
dNTPs, 1.5U Taq polymerase (Finnzymes, Finland), 5μl 10-
fold PCR buﬀer, and 5μl cDNA. PCR was carried out under
the following conditions: 5min at 95◦C, 1min denaturation
at 95◦C, 1min annealing at 60◦C, 1min extension at 72◦C
for 40 cycles, with an additional 10min extension for the
last cycle. Ampliﬁed products were separated on a 2% (w/v)
agarose gel, extracted and puriﬁed from agarose slices using
DNA Gel Extraction Kit (Millipore, USA), quantiﬁed by the
use of One Dscan/Zero Dscan software (Scanalytics Inc.,
USA), and then diluted in sterile water [12].
2.2. Western Blot Analysis. Tissue samples (control and
endometrial cancer) were homogenized in RIPA buﬀer
(1:10 v/w, ice-cold, pH 7,4), with the addition of protease
inhibitors cocktail (1mM EDTA, 1mM PMSF, 1μg/mL
aprotinin, 1μg/mL leupeptin, 1μg/mL pepstatin). Then
samples were centrifuged at 10,000g for 30min at 4◦Ca n d
the supernatant was analyzed further. Protein content was
measured with the BCA protein assay kit (Sigma). Bovine
serum albumin was used as a standard. Proteins (50μg)
were separated by SDS PAGE on 10% gel. Separated proteins
were transferred on nitrocellulose membranes (BioRad) in
transfer buﬀer (25mM Tris-HCl, pH 8.3, 192mM glycine,
20% methanol) at 14V in 4◦C. An equal sample loading was
conﬁrmed by Ponceau S stain. Then nitrocellulose blots were
placed in blocking buﬀer (5% nonfat milk in TBS-T) for
1h.Themembraneswereincubatedwithprimaryantibodies
against PPARα,P P A R β,P P A R γ (ab8934, ab23673, ab19481
Abcam, UK) or β-actin (ab3280, Abcam, UK), for 2h at 4◦C.
After three washings in TBS-T, membranes were incubated
withanalkalinephosphatase-conjugatedsecondaryantibody
(Sigma). Protein bands were scanned and quantiﬁed using a
Gel Doc EQ system (Bio-Rad). The total content of PPARs in
homogenate was normalized to the β-actin expression and
presented in arbitrary units (ODU-optical density units).
2.3. Immunohistochemical Tissue Staining. For immunohis-
tochemical studies 2-3 representative sections from each
case of the endometrial cancer and normal tissues were
selected. PPARs immunoexpression was evaluated by the
use of the polyclonal antibody (Santa Cruz Biotechnology,
USA) as recommended by the producer. Brieﬂy, the sections
were deparaﬃnized in xylenes and hydrated through graded
alcohols. Antigen unmasking was performed using heat
treatment in a microwave oven at 750W for 7 minutes in a
containerwith10mMsodiumcitratebuﬀer,pH6.0.Sections
were allowed to cool in the buﬀer at room temperature for
30 minutes and were rinsed in deionized H20 three times
for 2 minutes each. The endogenous peroxidase activity was
blocked with 1% hydrogen peroxide for 20 minutes. After
rinsing in PBS, the sections were incubated for 1 hour with
1.5% normal blocking serum in PBS. The blocking reagent
was removed, and then the sections were incubated with
primary antibody at 4◦C overnight using staining chamber
(The Binding Site, United Kingdom). Primary antibodies
were diluted in PBS with 1.5% normal blocking serum.
Omitting primary antibodies served as negative control.
After rinsing in three changes of PBS, a streptavidin-biotin-
peroxidase complex technique was used to reveal antibody-
antigen reactions (EnVision kit, Dako, Denmark). Staining
was routinely developed using 3,3 -diaminobenzidine as a
chromogen (Dako, Denmark). Sections were counterstained
with hematoxylin. Two independent pathologists, who werePPAR Research 3
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Figure 1: Immunohistochemical expression of PPARα in normal endometrium (a) and endometrial cancer (b) and PPARγ in normal
endometrium (c) and endometrial cancer (d). Some cells show enhanced accumulation of PPARs in nuclear and perinuclear area.
blinded to the clinicopathological data of the patients,
evaluated immunostainings with the use of light microscopy
(20x and 40x objectives). The evaluation of PPAR expression
was analyzed in 10 diﬀerent tumor ﬁelds, and the mean
percentage of tumor cells displaying positive staining was
scored. No staining of the cells was observed in any of the
tumor sections after omitting the ﬁrst antibody. Immuno-
histochemical expression for each PPAR isoform is presented
as the percentage (%) of the immunopositive cells present in
healthy endometrium or endometrial cancer tissue.
2.4. Statistical Analysis. Statistical comparisons were made
by using appropriate tests (Mann-Whitney U test, t-Student
test, and/or one-way ANOVA followed by the Newman-
Keul post hoc test). P<0.05 was considered statistically
signiﬁcant.
3. Results
All selected patients (n = 10) in the control group with
normalendometrialmucosahadnohypertensionordiabetes
nor obesity (BMI was 28,2), with the average age around
48,5 (range 35–54). The average age in the group of patients
with endometrial cancer was around 59 (range 43–73), and
there was no evidence either of obesity (BMI was 30,8) or
hypertension nor diabetes (data not shown).
3.1. Immunohistochemical Expression. Positive PPAR (-α,- β,
-γ) immunohistochemical staining was detected in normal
endometrial mucosa (for PPAR α: 57%, PPAR β: 55%, and
PPARγ:6 1 % )a sw e l la si ne n d o m e t r i a lc a n c e r s( f o rP P A R α:
78%; PPARβ: 77%; PPARγ: 84%) (Figure 1). With respect
to intensity of the staining, we observed more frequently
a stronger positive reaction in cancer cells than in healthy
mucosa, but not in all cases (data not shown). A trend
towards higher expression of PPAR α, β in endometrial
cancers was noticed (+21% and +22%, P = 0.067, resp.).
In opposite, EC cells showed lower expression for PPARγ
(−23%, P<0.05). Localization of the staining was similar
for all the PPARs isoforms. Immunopositive cells in normal
and endometrial cancer tissue were found broadly in nuclear
and perinuclear region (Figure 1).
3.2. PPARs mRNA Content. The mRNA content of all PPARs
was examined in normal endometrial mucosa (n = 10)
as well as in endometrial cancers (n = 35). The mRNA
expression of each PPAR isoform was signiﬁcantly higher
in normal endometrial tissue comparing with EC (PPARα:+
3,1–fold; PPARβ: +3,8-fold; PPARγ: +4,1-fold; P<0.05;
Table 1).
3.3. PPARs Protein Expression. Western blots analyses con-
ﬁrmed greater immunohistochemical expression of PPARα4 PPAR Research
Table 1: Expression of PPARs mRNA in normal and endometrial cancer tissues (∗Mann-Withney test).
Parameters (fmol/μgo fR N A ) Normal endometrium n = 10 Endometrial cancer n = 35
Median Low quartile High quartile Median Low quartile High quartile P∗
PPARα 3,136 0,77 7,113 0,986 0,5507 1,783 P<0.05
PPARβ 5,373 4,121 11,64 1,417 0,778 2,831 P<0.0001
PPARγ 7,148 5,568 19,77 1,721 0,601 4,883 P<0.0001
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Figure 2: The expression of PPARs (α, β, γ) proteins (optical
density units (ODU)) in normal and endometrial cancer tissues.
∗P<0.05 (CTRL); normal endometrium versus endometrial
cancer (EC).
andPPARβ isoformsinendometrial cancertissuecomparing
with normal mucosa (PPARα: +0,7-fold; PPARβ: +2,0-fold;
P<0.05; Figure 2). An opposite eﬀect was observed for the
expression of PPARγ, which was signiﬁcantly lower in EC
(PPARγ: −1,5-fold; P<0.05; Figure 2).
4. Discussion
The present study was undertaken to characterize the
expression of PPARs in endometrial cancers (EC) at the
transcriptional (mRNA) and posttranscriptional (proteins)
levels.Immunohistochemistrywasappliedfortheevaluation
of the PPARs immunoexpression and subcellular distribu-
tion. Protein expression was further quantiﬁed by Western
Blot technique. To the best of our knowledge, this is the ﬁrst
study to report that only the expression of PPARα and β is
relatively higher in EC, but not PPARγ. The disassociation
of mRNA content and respective protein product were also
foundinendometrialcancers.ThisdiscrepancyofthemRNA
contentandtheexpressionofrespectiveproteiniscommonly
observed in neoplastic tissues [12, 13].
4.1. PPARγ Expression. We found reduced immunohisto-
chemical PPARγ expression in EC, which is consistent with
other reports showing rather moderate immunoreactivity
of PPARγ expression in endometrial carcinoma cells [14,
15]. This relatively low PPARγ expression was also found
in other tumor cells, and some studies begin to suggest
that PPARγ agonists may inhibit cell proliferation in the
neoplastic cell lines [16–18]. It seems highly possible, since
several in vitro studies have revealed that pioglitazone, a
PPAR-γ agonist, induces cell diﬀerentiation [19] and several
clinical studies have demonstrated that the activation PPAR-
γ increases the degree of histopathological diﬀerentiation
of liposarcoma [19, 20]. However, it is not the case for
all neoplastic transformation, as others demonstrated that
highly malignant cancer cell lines are characterized by higher
expression of PPARγ and these data suggest that PPARγ may
act in a cancer-permissive fashion [21, 22].
4.2. PPARα and/or PPARβ Expression. In our study we found
increased expression (immunoreactivity further quantiﬁed
by Western Blot) of both PPARα and PPARβ isoforms
in EC compared to healthy endometrium. This ﬁnding
may imply a possible role for both PPARs (α and β)i n
neoplastic transformation of endometrial cells. However,
we are aware of the limitations of our study. First the
study was limited to one type of endometrial cancers
(FIGO 1), and an open question remains whether there is
a progression of the PPARs expression in more advanced
endometrial cancers. Secondly, some reports suggest that
there is a considerable background immunoreactivity when
PPARs expression is measured by immunohistochemistry
[23, 24]. This is important as there are a number of
reports showing either an increase or decrease in PPAR (α
and β) immunohistochemical expression, even in the same
tissue [23, 25]. Nonetheless, the speculations concerning
PPARα/β relative expression and function in cancer cells
are further based on their opposite to PPARγ physiological
roles. PPARγ is thought to be primarily involved in processes
that augment diﬀerentiation of the cells and/or storage of
energy, and PPARsα/β activation presumably enhances the
processes related to the fuel expenditure. This suggests a
possibility that neoplastic cells may have greater PPARα/β
expression/activity, which should activate genes controlling
cellular metabolism and result in faster metabolic rates of
cancer cells. From rodent studies it is becoming evident that
chronic treatment with PPARα agonist induces incidences
of liver tumors through a mechanism, that results in an
increase of both cellular proliferation and oxidative stress
[26]. However, such a tumorigenic inﬂuence of PPARα
activationwasfoundonlyinanimalstudies.Asfarthereisno
evidence that PPARα agonists such as ﬁbrates are associated
with elevated risk of cancer in humans [27, 28].
In summary, we provide evidence for altered expression
of diﬀerent PPAR isoforms in endometrial cancer cells,PPAR Research 5
namely, greater expression of PPARα and PPARβ,w i t h
concomitant reduction of PPARγ in EC.
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